Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
NuGEN Technologies provides scientists and clinicians with innovative and reliable sample-preparation technologies for targeted genomic analysis and diagnostics.
Lohmann & Rauscher, a leading international provider of high-quality medical devices and hygiene products for hospitals, medical practices and consumers for over 160 years, is looking to identify partners to drive innovation in advanced wound care over the next decade.
Pacific Edge has expanded the international market for two new molecular tests that provide better detection and management of urothelial cancer. To download the full article, please sign in.
MD Anderson Cancer Center is one of the largest and most respected centers of its kind in the world, with a wealth of resources and expertise to offer biopharmaceutical companies aiming to catapult next-generation cancer therapies into the clinic.
The Institut Pasteur is harnessing a powerful combination of in-house research strengths to explore the relationship between the microbiome and the brain. The institute is looking for partners eager to take advantage of this unique opportunity to learn more about the gut–brain axis.
Using a unique combination of computational chemistry, pharmacology and cheminformatics methods, Re-Pharm is successfully reprofiling marketed compounds as early stage candidates ready for partnering.
Three collaborative platforms—a Center for Innovation (COI), a tripartite industry-academia group (DUCR, TLO and UTEC) and the Translational Research Initiative (TRI)—showcase the University of Tokyo’s commitment to the development and commercialization of new healthcare technologies.
A leader in CNS specialty medicine sales in the United States and in the top five globally, Teva Pharmaceuticals is actively looking to expand its CNS portfolio further.
New company Astrocyte Pharmaceuticals is pioneering a novel approach to healing a damaged brain that involves activating energy supplies in astrocytes, the abundant star-shaped brain cells with a central role in repairing CNS injury.
Three collaborative platforms—a Center for Innovation (COI), a tripartite industry-academia group (DUCR, TLO and UTEC) and the Translational Research Initiative (TRI)—showcase the University of Tokyo’s commitment to the development and commercialization of new healthcare technologies. To download the full article, please sign in.
Crescendo Biologics is poised to significantly impact the world of antibody therapeutics with the enormous potential of its Humabody technology and its product-discovery and engineering capabilities.
Sanford Burnham Prebys Medical Discovery Institute is an independent, nonprofit biomedical research institute that combines deep expertise in fundamental and translational science to discover innovative medicines and diagnostics.
With its unique LentiVector platform and expanding state-of-the-art manufacturing facilities, Oxford BioMedica has established itself as the partner of choice for companies developing advanced therapy medicinal products.
